(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of 11.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.96%.
Abivax Sa's revenue in 2024 is $5,022,826.On average, 2 Wall Street analysts forecast ABVX's revenue for 2024 to be $315,902,666, with the lowest ABVX revenue forecast at $314,014,802, and the highest ABVX revenue forecast at $317,790,531. On average, 2 Wall Street analysts forecast ABVX's revenue for 2025 to be $319,049,107, with the lowest ABVX revenue forecast at $314,014,802, and the highest ABVX revenue forecast at $324,083,413.
In 2026, ABVX is forecast to generate $466,617,185 in revenue, with the lowest revenue forecast at $314,014,802 and the highest revenue forecast at $619,219,569.